Table 4.
Resource Use, Costs, Health Benefits, and Cost-Effectiveness
| Strategy | RNTCP Expenditures Needed Relative to Current Expenditures | Case Notifications* | Avg Lifetime Costs | s.e. | Avg Lifetime QALYs | s.e. | ICER at Mean |
|---|---|---|---|---|---|---|---|
| No intervention | 100% | 131 | 506.87 | 0.09 | 24.740 | 0.00225 | NA |
| GeneXpert for DST | 104% | 131 | 507.27 | 0.12 | 24.743 | 0.00226 | dominated |
| PPM | 109% | 138 | 507.87 | 0.11 | 24.754 | 0.00228 | 72.06 |
| PPM + GeneXpert for DST | 112% | 211 | 508.12 | 0.10 | 24.756 | 0.00213 | 144.52 |
| GX for all diagnosis | 384% | 137 | 523.61 | 0.13 | 24.764 | 0.00207 | dominated |
| PPM + GeneXpert for all diagnosis | 394% | 243 | 524.57 | 0.12 | 24.771 | 0.00236 | 1103.58 |
*
Annual case notifications per 100,000 for first-line public sector treatment over 2015–2025